Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
TEVA PHARMACEUTICALS DEVELOPMENT, INC., v. AMICUS THERAPEUTICS U.S., INC.
Case Number:
2:21-cv-03105
Court:
Nature of Suit:
Other Statutes: Other Statutory Actions
Judge:
Companies
Sectors & Industries:
-
September 03, 2021
Teva Drops Claim That Rival Slowed Generic Development
Teva Pharmaceuticals has voluntarily dropped its claims against Amicus Therapeutics Inc., which it had accused of hoarding supplies of a costly brand-name medication in violation of a new federal law aimed at providing generic drug manufacturers with predictable supplies of new medicines to aid in bringing unbranded alternatives to market.
-
July 13, 2021
Teva Says Rival Hoarding Drug To Slow Generic Development
A Teva Pharmaceuticals subsidiary on Tuesday accused Amicus Therapeutics Inc. of hoarding supplies of a costly brand-name medication, in violation of a new federal law aimed at providing generic-drug makers with predictable supplies of new medicines to aid in bringing unbranded alternatives to market.